{"id":939315,"date":"2026-02-24T08:06:54","date_gmt":"2026-02-24T13:06:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/"},"modified":"2026-02-24T08:06:54","modified_gmt":"2026-02-24T13:06:54","slug":"kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","title":{"rendered":"Kymera Therapeutics to Participate in Upcoming March Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WATERTOWN, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zFHqqfjvWZLu_XqbkJRNHyUX52KyGKJUpeUzUrbjoS9e2gxSYde7wUumHuolMqub4aj59QD-ir3xmYJ7LWCayjNVfxLaHFwZZLIS7rqEeFY=\" rel=\"nofollow\" target=\"_blank\">Kymera Therapeutics, Inc.<\/a> (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:\u00a0<\/p>\n<ul type=\"disc\">\n<li>TD Cowen 46<sup>th<\/sup> Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;<\/li>\n<li>Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; and<\/li>\n<li>Barclays 28<sup>th<\/sup> Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET.<\/li>\n<\/ul>\n<p>In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit on March 9 and March 11, respectively.<\/p>\n<p>Live webcasts of the presentations will be available under \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8wxC5BB8lx5PPOlMrDWlv7YFLQo3ZTLnGKcpptitY6x-EIUfC9o2jLsMzBiQIIsT6Gzvcz5dYq7aoA4k5m6CSp1sKkF8MMTwE52zicRe_u7mb6n2sXWXL4gJ_vnsqiNc\" rel=\"nofollow\" target=\"_blank\">News and Events<\/a>\u201d in the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N7EAXF2-QAvMCXLQ60AXyoK_2jAzT5iBdi55RJYjYjWDS52lJQ4XXTyPX8JTGdTiH_mzjIhoUFa5KWdGfiAOGnvvAp9-BOjm-U36GP7k-3E=\" rel=\"nofollow\" target=\"_blank\">www.kymeratx.com<\/a>. Replays of the webcasts will be archived and available following the events.\u00a0<\/p>\n<p>\n        <strong>About Kymera Therapeutics<\/strong>\u00a0<br \/>Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients\u2019 lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston\u2019s top workplaces for the past several years. For more information about our science, pipeline and people, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N7EAXF2-QAvMCXLQ60AXyoSMrM5rXkRoJqK40ixwzhqs78RxAtGUvYgI0VZY20TWpG7QcfRiQxhjmf75ARjLThe_-xpNBeLTGJvpZfMcHao=\" rel=\"nofollow\" target=\"_blank\">www.kymeratx.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y3BDjGLM0bUX505ISsLry5UwV8oztjYCHyj1m5xYX3afYCXDA_yW1nJfmAmAK9IwXTnzBArlfDYhC_jvuTfUFw==\" rel=\"nofollow\" target=\"_blank\">X<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KlK5ocWF-co4rS_R-cBct4akDG-VR1zT5doy1DN7JvXey87iGfjfpQk15mX4x5Cz2pF3Kf_cDJuJ522r76NQh0xvUpBJpKecDmWwPCvsJPwBCRggaTLE0Vh9lVfulW37\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.\u00a0<\/p>\n<p>\n        <strong>Investor Contact:<\/strong>\u00a0<br \/>Justine Koenigsberg<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ou6cL2AmgoA65pnKAw-HaNoL7N92EOJFnVo2J0kBIgwfhgfASypaZx0FMrz5FxRUW4-IlcpzPQwiaVCUGCVYnhWTxyTp1_37Ek3FOWWM34U=\" rel=\"nofollow\" target=\"_blank\">investors@kymeratx.com<\/a><br \/>857-285-5300\u00a0<\/p>\n<p>\n        <strong>Media Contact: <\/strong><br \/>\n        <br \/>Matthew Henson <br \/>Vice President, Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r7nzSyA_z0kMrk-LHl8V5TT1ajN-WoXJBYwEA5wCIT_iPqWLm-ZHn-GAfi0LyEt0njk-ACgTCrno5416MdcLstBo-ix0Cu9nC3_Qro37DA4=\" rel=\"nofollow\" target=\"_blank\">mhenson@kymeratx.com<\/a><br \/>857-285-5300<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2E0ODQ5ZDQtM2ExMi00NGE3LTljYjItNDI0M2Y3YmRkMWQ5LTEyMTIzODUtMjAyNi0wMi0yNC1lbg==\/tiny\/Kymera-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:\u00a0 TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET; Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; and Barclays 28th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET. In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit on March 9 and March 11, respectively. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kymera Therapeutics to Participate in Upcoming March Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-939315","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymera Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymera Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:\u00a0 TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET; Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; and Barclays 28th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET. In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit on March 9 and March 11, respectively. &hellip; Continue reading &quot;Kymera Therapeutics to Participate in Upcoming March Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T13:06:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kymera Therapeutics to Participate in Upcoming March Investor Conferences\",\"datePublished\":\"2026-02-24T13:06:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\"},\"wordCount\":310,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\",\"name\":\"Kymera Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=\",\"datePublished\":\"2026-02-24T13:06:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymera Therapeutics to Participate in Upcoming March Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymera Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Kymera Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk","og_description":"WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:\u00a0 TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET; Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; and Barclays 28th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET. In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit on March 9 and March 11, respectively. &hellip; Continue reading \"Kymera Therapeutics to Participate in Upcoming March Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-24T13:06:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kymera Therapeutics to Participate in Upcoming March Investor Conferences","datePublished":"2026-02-24T13:06:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/"},"wordCount":310,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/","name":"Kymera Therapeutics to Participate in Upcoming March Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=","datePublished":"2026-02-24T13:06:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODk1MiM3NDQ4MjgzIzIyMDA4MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-march-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kymera Therapeutics to Participate in Upcoming March Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/939315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=939315"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/939315\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=939315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=939315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=939315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}